Laura A Bolte, Karla A Lee, Johannes R Björk, Emily R Leeming, Marjo J E Campmans-Kuijpers, Jacco J de Haan, Arnau Vich Vila, Andrew Maltez-Thomas, Nicola Segata, Ruth Board, Mark Harries, Paul Lorigan, Elisabeth G E de Vries, Paul Nathan, Rudolf Fehrmann, Véronique Bataille, Tim D Spector, Geke A P Hospers, Rinse K Weersma
IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, is a poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB...
February 16, 2023: JAMA Oncology